Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.49 |
| ▸ | NMT1 | P30419 | 4/20 | 0.47 |
| ▸ | NMT2 | O60551 | 3/20 | 0.47 |
| ▸ | GLP1R | P43220 | 8/20 | 0.42 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16156108 | 1.00 | NOD1 (0.49) | NOD1NMT1NMT2GLP1RGLO1 | |
| SCHEMBL17375884 | 0.98 | NMT1 (0.47) | NOD1NMT1NMT2GLP1RGLO1 | |
| SCHEMBL21100058 | 0.98 | NMT1 (0.47) | NOD1NMT1NMT2GLP1RGLO1 | |
| SCHEMBL17682348 | 0.96 | NOD1 (0.52) | NOD1NMT1NMT2GLP1RGLO1 | |
| SCHEMBL21418066 | 0.95 | NOD1 (0.47) | NOD1NMT1NMT2GLP1RGLO1 | |
| SCHEMBL20375263 | 0.95 | NOD1 (0.47) | NOD1NMT1NMT2GLP1RGLO1 | |
| SCHEMBL19308014 | 0.95 | NMT1 (0.49) | NOD1NMT1NMT2GLP1RGLO1 | |
| SCHEMBL19867245 | 0.95 | NMT1 (0.49) | NOD1NMT1NMT2GLP1RGLO1 | |
| SCHEMBL19308062 | 0.94 | NOD1 (0.51) | NOD1NMT1NMT2GLP1R | |
| SCHEMBL14167356 | 0.93 | NOD1 (0.50) | NOD1NMT1NMT2GLP1RGLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170145069-A1 | GLP-1 Derivatives | NOVO NORDISK AS (DK) | 2017-05-25 | — | — | US | disclosed |
| US-20140303083-A1 | GLP-1 Derivatives | NOVO NORDISK A/S (DK) | 2014-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145069-A1 | GLP-1 Derivatives | GLP1R, GIPR, GCG | NOD1 667/4885NMT1 882/4885NMT2 1122/4885 |
| US-20140303083-A1 | GLP-1 Derivatives | GLP1R, GIPR, GCG | NOD1 483/4885NMT1 1096/4885NMT2 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.